全文获取类型
收费全文 | 425篇 |
免费 | 25篇 |
国内免费 | 8篇 |
专业分类
基础医学 | 13篇 |
临床医学 | 39篇 |
内科学 | 115篇 |
皮肤病学 | 3篇 |
神经病学 | 25篇 |
特种医学 | 26篇 |
外科学 | 15篇 |
综合类 | 64篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 125篇 |
中国医学 | 20篇 |
肿瘤学 | 11篇 |
出版年
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 8篇 |
2020年 | 4篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 6篇 |
2015年 | 10篇 |
2014年 | 14篇 |
2013年 | 33篇 |
2012年 | 14篇 |
2011年 | 18篇 |
2010年 | 10篇 |
2009年 | 15篇 |
2008年 | 15篇 |
2007年 | 14篇 |
2006年 | 18篇 |
2005年 | 15篇 |
2004年 | 12篇 |
2003年 | 17篇 |
2002年 | 20篇 |
2001年 | 13篇 |
2000年 | 12篇 |
1999年 | 10篇 |
1998年 | 16篇 |
1997年 | 15篇 |
1996年 | 15篇 |
1995年 | 12篇 |
1994年 | 23篇 |
1993年 | 12篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 13篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 6篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1974年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有458条查询结果,搜索用时 93 毫秒
1.
2.
目的:观察前列地尔联合双嘧达莫对尿毒症患者内瘘的影响。方法:将55例非透析尿毒症患者实施动静脉内瘘手术,术后分为对照组和治疗组。对照组给予双嘧达(25 mg,3次/日)治疗,治疗组在对照组基础上联合前列地尔(10μg,1次/日)治疗2周。治疗过程中,观察2组患者凝血功能、纤维蛋白原及血液黏滞度;比较2组患者内瘘成熟时间、血流量及内瘘狭窄率。结果:2组患者凝血功能较治疗前均有所延长(P<0.05),但组间比较无差异。治疗组血液黏滞度较对照组显著下降(P<0.05)。与对照组相比,治疗组内瘘成熟时间显著缩短,且首次透析时内瘘血流量显著增加(P<0.05)。治疗组内瘘狭窄率与对照组相比显著下降(P<0.05)。结论:前列地尔联合双嘧达莫可促进尿毒症患者内瘘成熟,减少内瘘狭窄发生。 相似文献
3.
目的 观察中国健康受试者空腹和高脂高热量饮食情况下口服双嘧达莫片的药动学特征。方法 75名健康受试者分别在空腹或高脂饮食条件下单剂量口服双嘧达莫片25 mg,分别在不同时间点采集静脉血样。采用LC-MS/MS测定人血浆中双嘧达莫的浓度,用PhoenixWinNonlin 8.0软件按非房室模型计算药动学参数。结果 空腹和高脂饮食后双嘧达莫片的主要药动学参数如下:Cmax分别为(594.69±172.14),(333.64±167.18) ng·mL-1,餐后较空腹Cmax降低了43.9%(P<0.01);t1/2分别为(9.87±4.21),(10.57±3.75) h;AUC0-t分别为(1 733.22±715.49),(1 268.61±571.07) ng·mL-1·h,AUC0-∞分别为(1 801.69±707.61),(1 353.64±602.29) ng·mL-1·h,餐后较空腹AUC0-t及AUC0-∞分别降低26.8%,24.9%(P<0.01);Tmax中位数(范围)分别为0.75[0.50,5.00] h和1.50[0.49,4.52] h,餐后服药的Tmax明显延迟(P<0.01)。结论 高脂饮食后服药较空腹条件下服药,Cmax、AUC0-t及AUC0-∞均明显降低,Tmax明显延迟,说明食物对双嘧达莫片的吸收速度、吸收程度均有显著影响。 相似文献
4.
目的:观察银杏达莫联合神经节苷酯(GM1)治疗脑卒中后血管性痴呆(VD)的疗效. 方法:选取我院收治的80例脑卒中后血管性痴呆患者,依据用药方案分为银杏达莫联合GM1组40例(记为观察组),银杏达莫组40例(记为对照组).测定给药前后的简易精神状态量表(MMSE)及Barthel指数评分(MBI),对比两组疗效.结果:观察组的MMSE评分、Barthel指数评分及总有效率均显著高于对照组(P<0.05).结论:银杏达莫联合GM1治疗脑卒中后VD能有效提高认知能力及日常生活能力且安全有效,值得推广. 相似文献
5.
目的:观察青紫汤加减治疗小儿过敏性紫癜的临床疗效。方法:选取过敏性紫癜患儿44例,随机分为对照组和治疗组各22例,对照组给予扑尔敏、潘生丁等西药常规治疗,治疗组在对照组治疗的基础上加用青紫汤加减治疗。两组均1周为1个疗程,1个疗程后比较两组疗效。结果:对照组有效率为81.82%,治疗组有效率为95.45%,两组有效率比较差异有统计学意义(P0.05),治疗组优于对照组。结论:青紫汤加减治疗小儿过敏性紫癜疗效显著。 相似文献
6.
Background:In recent years, the incidence rate of hypertensive nephropathy has been increasing quickly, which has been a major threat to people''s health. Renin-angiotensin-aldosterone system blockers have certain curative effects. However, there are some patients having serious adverse reactions, and the benefit population is limited, so the treatment of hypertensive renal damage is necessary to have beneficial supplement. More and more clinical studies have shown that ginkgo leaf extract and dipyridamole injection (GDI) combined with antihypertensive drugs has achieved good results in the treatment of hypertensive renal damage. It is supposed to be a supplementary treatment in hypertensive nephropathy.Objectives:To systematically assess the efficacy and safety of GDI combined with antihypertensive drugs on hypertensive renal injury.Methods:Seven databases including PubMed, Cochrane Library, Embase, Wanfang database, China biomedical literature service system (Sino Med), VIP Chinese Sci-tech journal database (VIP), and China national knowledge internet (CNKI) were retrieved to collect randomized controlled trials (RCTs) in the experimental group containing combined therapy of hypertensive nephropathy with GDI and antihypertensive drugs. The retrieval time was from the establishment of database to July 8, 2020. Two researchers independently selected literature, extracted data, and evaluated the risk of bias in the study. The methodological quality was evaluated with Cochrane handbook and meta-analysis was performed with Stata 14.0 software.Results:Eight studies were included in this study which involved 556 patients. The meta-analyses indicated that, compared with using antihypertensive drugs alone, combined treatment of GDI with antihypertensive drugs can decrease 24-hour urinary total protein (weighted mean difference [WMD] –0.61, 95% confidence interval [CI]: –0.82, –0.39; k = 6, P ≤ .001), blood urea nitrogen (WMD –1.27, 95% CI: –2.45, –0.10; k = 6, P = .033, serum creatinine (WMD –29.50, 95% CI: –56.44, –2.56; number of estimates [k] = 6, P = .032).Conclusions:Our meta-analyses showed that GDI combined with antihypertensive drugs can improve the renal function of hypertensive patients with renal injury. 相似文献
7.
目的观察银杏达莫注射液对急性脑梗死患者血清白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)水平的影响。方法 80例急性脑梗死患者随机分为两组,治疗组予以常规措施并加银杏达莫注射液治疗,对照组仅用常规治疗。观察治疗前后血清IL-1β、IL-6水平的变化。结果两组治疗后血清I L-1β、IL-6的浓度较治疗前有明显降低,但治疗组降低较对照组更显着(P<0.05)。结论银杏达莫注射液可显著降低急性脑梗死患者血清IL-1β、IL-6的水平而降低炎症反应,在治疗急性脑梗死中起重要作用。 相似文献
8.
目的:观察脑梗塞患者应用银杏达莫联合奥扎格雷注射液治疗的临床疗效。方法:我科收治的脑梗塞患者共70例,随机分为银杏达莫联合奥扎格雷注射液治疗组(观察组)和单用奥扎格雷注射液治疗组(对照组)各35例,观察两组的治疗效果及不良反应发生率。结果:观察组中总有效率为97.13%,明显高于对照组的总有效率85.72%。两组对比,P<0.05,有统计学意义;不良反应发生率两组未见明显异常。结论:银杏达莫联合奥扎格雷注射液治疗临床效果显著且安全,临床可应用。 相似文献
9.
10.
Petretta M Spinelli L Marciano F Vicario ML Testa G Signorini A Bonaduce D 《Clinical cardiology》1999,22(3):201-206
BACKGROUND: Analysis of heart rate variability (HRV) is a valuable noninvasive method for quantifying autonomic cardiac control in humans and has been utilized during dipyridamole echocardiographic test to differentiate positive from negative test results. HYPOTHESIS: We aimed to evaluate, by means of HRV analysis, the influence of the angiographic severity of coronary artery disease on cardiac autonomic control during dipyridamole-induced myocardial ischemia. METHODS: We analyzed RR interval variability changes during dipyridamole-induced myocardial ischemia in 31 selected patients (mean age 54 +/- 9 years) with available coronary angiography and positive dipyridamole echocardiographic test. Spectral components of HRV were assessed by means of wavelet transform analysis for the last 5 min before the beginning of the test (baseline) and for 5 min after the onset of ischemia-related events (peak dipyridamole effect). RESULTS: Patients were divided into three groups according to the number of coronary diseased vessels (Group A, single-vessel disease; Group B, double-vessel disease; Group C, triple-vessel disease). No difference was detectable at baseline among the three groups. After dipyridamole, low-frequency power, a measure of sympathetic modulation of heart rate, increased and echocardiographic wall motion score index worsened in all groups (p < 0.001). The increase in low-frequency power was more evident in Group C patients than in the other two groups (p < 0.005). Furthermore, after dipyridamole, a direct correlation was found between low-frequency power and wall motion score index (r = 0.59; p < 0.001). CONCLUSIONS: These data suggest that HRV analysis performed during dipyridamole echocardiographic test provides useful information to assess the severity of coronary artery disease. 相似文献